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Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel 
disease that may become intractable when treated with 
conventional medications such as aminosalicylates, 
corticosteroids, and azathioprine. The herbal medicine 
Qing Dai has traditionally been used in Chinese medi-
cine to treat UC patients, but there is a lack of pub-
lished data on the efficacy of Qing Dai in UC treatment. 
We report several cases of patients with intractable 
UC who take Qing Dai in a retrospective observational 
study. Furthermore, we explore the mechanisms of ac-
tion of Qing Dai. Nine patients with active UC who re-
ceived conventional medications but wished to receive 
Qing Dai as an alternative medication were included 
in our analysis. The UC severity level was determined 
based on the clinical activity index (CAI). Additionally, 5 
of the 9 patients were endoscopically evaluated accord-
ing to the Matts grading system. Each patient received 
2 g/d of Qing Dai orally and continued taking other 
medications for UC as prescribed. Electron spin reso-
nance was applied to explore the mechanisms of action 
of Qing Dai. After 4 mo of treatment with Qing Dai, the 
CAI score decreased from 8.3 ± 2.4 to 2.4 ± 3.4 (mean 
± SD; P  < 0.001). Similarly, the endoscopic Matts grade 
decreased from 3.4 ± 0.5 to 2.2 ± 0.8 (P  = 0.02). Six 
of 7 patients who were on prednisolone upon enroll-
ment in the study were able to discontinue this cortico-
steroid. Electron spin resonance revealed that Qing Dai 
possesses strong hydroxyl radical scavenging activity. 
Qing Dai showed significant clinical and endoscopic ef-
ficacy in patients who failed to respond to conventional 
medications. Scavenging of hydroxyl radicals appears 
to be a potential mechanism through which Qing Dai 
acts, but the significance of the scavenging ability of 
Qing Dai with respect to the anti-inflammatory effect in 
UC patients warrants further investigation.
© 2013 Baishideng. All rights reserved.
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Core tip: Nine intractable ulcerative colitis patients us-
ing the herbal medicine Qing Dai were observed in a 
retrospective observational study. After 4 mo of treat-
ment, clinical activity and endoscopic findings improved 
dramatically in most patients. Electron spin resonance 
revealed that Qing Dai has a strong radical scavenging 
effect.
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INTRODUCTION
The prevalence of  ulcerative colitis (UC) is increasing 
worldwide and has reached a total of  130000 cases in 
Japan. Clinical practice guidelines issued by the Japanese 
Ministry of  Health, Labor and Welfare recommend 
aminosalicylates, sulfasalazine, or 5-aminosalicylic acid 
(5-ASA) followed by corticosteroids [prednisolone (PSL)] 
or azathioprine (AZA) as the standard treatment for UC 
patients. Recently, infliximab (IFX) and tacrolimus have 
become available and are used clinically as novel medica-
tions for patients with UC. However, some patients do 
not respond to these pharmacological interventions; UC 
in such patients is called refractory or intractable. The 
herbal medicine Qing Dai is also known as Indigo natu-
ralis and is extracted from plants such as Strobilanthes cusia 
and Isatis tinctoria. Qing Dai contains natural ingredients 
such as indigo, indirubin, isoindigotin, and nimbosterol. 
In China, Qing Dai has been traditionally used as an an-
tipyretic, an antiphlogistic, and as a hemostatic remedy. 
Qing Dai enemas have been used for ulcerative proctitis 
and are currently described in Chinese medical guidelines 
for the treatment of  UC. However, until now, no report 
has been published describing the efficacy of  orally ad-
ministered Qing Dai in UC patients.
CASE REPORT
Cases
Nine UC patients (7 men and 2 women, listed in Table 
1) who voluntarily received Qing Dai between 2008 and 
2011 were retrospectively evaluated. Patients who did 
not respond to 5-ASA and PSL or IFX were defined as 
“intractable”. One patient who was not intractable but 
refused to add PSL or IFX was included in the analy-
sis. The average age of  the patients was 34 years with a 
range of  16-75 years. All patients purchased Qing Dai 
from Seishinshoyakudo (Tokyo, Japan), a company that 
imports Qing Dai from China and sells it at a price of  
4200 Japanese yen (US $50) per 500 g. Qing Dai was 
provided as powder, and each patient took 1 g of  Qing 
Dai orally twice a day without wrapping, according to the 
manufacturer’s recommendations. All 9 patients were on 
5-ASA, and 7 patients were also on PSL. 5-ASA and PSL 
were taken at the recommended dose for at least 8 wk 
prior to the initiation of  Qing Dai; however, unique cases 
include patient D, whose pharmacological regimen was 
changed from 3 g/d of  Pentasa (Ferring Pharmaceuticals, 
Malmö, Sweden) to 3.6 g/d of  Asacol (Warner Chilcott, 
Dublin, Ireland) 4 d before the start of  Qing Dai and 
patient F, whose prescription was changed from 4 g/d of  
Pentasa to 3.6 g/d of  Asacol 3 d before taking Qing Dai. 
The clinical activity index (CAI)[1] of  the patients before 
taking Qing Dai and 1, 2, and 4 mo after initially taking 
Qing Dai and the endoscopic Matts grade[2] before and 
after treatment with Qing Dai were retrospectively col-
lected from clinical records because those data had been 
routinely recorded for all UC patients.
Electron spin resonance
To investigate the mechanisms of  action of  Qing Dai, we 
performed electron spin resonance (ESR) spectroscopy 
by using the spin-trapping reagent 5-(2,2-dimethyl-1,3-
propoxy cyclophosphoryl)-5-methyl-1-pyrroline N-oxide 
(CYPMPO)[3]. Hydroxyl radicals were produced in an 
aqueous solution containing 50 μL of  2 mmol/L H2O2 
dissolved in 0.1 mol/L phosphate buffer. Fifty microliters 
of  8.9 mmol/L DMPO with or without 2.5, 25, or 250 
μg/mL Qing Dai was incubated for 60 s after the addi-
tion of  50 μL of  0.2 mmol/L FeSO4, and results were 
obtained using a JEOL-TE X-Band spectrometer (JEOL, 
Tokyo, Japan).
Ethical consideration
All 9 patients began taking Qing Dai voluntarily. None-
theless, for this paper, written informed consent was ob-
tained from all of  the patients included in the analysis.
Statistical analysis
The data for CAI and Matts grade score were analyzed by 
a paired t-test using Excel 2010 (Microsoft, United States) 
with the add-in software Statcel 3 (OMS publishing Co., 
Saitama, Japan). Differences corresponding to a P value 
< 0.05 were considered statistically significant.
Clinical and endoscopic efficacy of Qing Dai
The average CAI score (mean ± SD) decreased from 
8.3 ± 2.4 to 2.4 ± 3.4 (P < 0.001) (Figure 1A). This ef-
fect persisted unless the patient withdrew from Qing Dai 
treatment. Patients A and C showed recurrence of  UC af-
ter cessation of  Qing Dai. However, their CAI score im-
mediately recovered upon re-administration of  Qing Dai. 
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Table 1  Patient characteristics including lesion type and 
ulcerative colitis duration and treatment
Patient Sex Age 
(yr)
Type of UC 
Lesion
Duration of 
UC (mo) 
Ongoing treatment 
at time of Qing Dai 
initiation
A M 16 Proctitis 18 5-ASA, PSL
B M 36 Left-sided 
colitis
65 5-ASA, IFX
C M 35 Proctitis 96 5-ASA, PSL, CAP
D M 33 Pancolitis 60 5-ASA, PSL, AZA, 
IFX
E M 31 Left-sided 
colitis
40 5-ASA, PSL, AZA
F M 27 Left-sided 
colitis
32 5-ASA, PSL, CAP, 
IFX
G F 26 Proctitis   6 5-ASA
H F 29 Left-sided 
colitis
  8 5-ASA, PSL
I M 75 Left-sided 
colitis
74 5-ASA, PSL, AZA
Nine UC patents (7 men and 2 women) were included in this study. The 
type of colitis lesion, the duration of UC and the ongoing treatment at the 
time of Qing Dai initiation are shown. UC: Ulcerative colitis; M: Male; F: 
Female; 5-ASA: 5-aminosalicylates; PSL: Prednisolone; IFX: Infliximab; 
CAP: Cytapheresis; AZA: Azathioprine.
Five patients, including 3 patients with left-sided colitis, 
1 patient with pancolitis and 1 patient with proctitis, 
were monitored by endoscopy. The average time interval 
between endoscopies was 7 mo (range 2-10 mo). The en-
doscopic Matts grade (Figure 1B) also decreased from 3.4 
± 0.5 to 2.2 ± 0.8 (P = 0.02). Six of  the 7 patients (86%) 
who were also taking PSL were able to discontinue this 
corticosteroid.
Patient E, a 28-year-old man who presented with 
hematochezia was diagnosed as having left-sided UC 
and demonstrated remarkable benefit from Qing Dai 
therapy. Initially, patient E was prescribed 4 g/d sul-
fasalazine and 40 mg/d PSL for the treatment of  UC, 
and the hematochezia rapidly disappeared. However, the 
hematochezia recurred as the patient reduced his intake 
of  PSL. Thus, patient E required the dose of  PSL to be 
increased several times, and treatment with AZA and 
cytapheresis failed to provide long-term improvement. 
Patient E met our criteria for refractory UC. After 3 
years of  treatment, patient E began to use Qing Dai of  
his own volition. One month after treatment with Qing 
Dai, hematochezia in patient E was resolved, and the 
CAI score decreased from 9 to 4. The serum C-reactive 
protein level also decreased from 1.33 mg/dL to 0.11 
mg/dL. The CAI score fell to 0 after 3 mo of  treatment 
with Qing Dai, and patient E was withdrawn from PSL 
and AZA after 8 mo of  Qing Dai treatment. Notably, 
this effect of  Qing Dai therapy persisted for more than 
2 years. The endoscopic findings are shown in Figure 
2A and B. The ulcers completely disappeared and only 
erythema was observed. In contrast, patient D did not 
respond to Qing Dai, and required the administration of  
conventional medications.
Safety
Although no serious adverse side effects were reported in 
patients consuming Qing Dai, 2 patients developed mild 
headaches while taking Qing Dai. The headaches disap-
peared upon reduction of  the dose of  Qing Dai by half.
Hydroxyl radical scavenging effect of Qing Dai
As shown in Figure 3, without Qing Dai, the ESR spec-
trum agreed with CYPMPO-OH, a hydroxyl radical ad-
duct trapped by CYPMPO. The reduction in the signal 
intensity of  CYPMPO-OH reflected the hydroxyl radical 
scavenging ability of  Qing Dai, and the results of  treat-
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Figure 1  The clinical activity index score and endoscopic Matts grade before and after Qing Dai initiation. A: The score markedly improved from 8.3 ± 2.4 to 2.4 
± 3.4 (mean ± SD; t-test, P < 0.001) after the initiation of Qing Dai. The line plotted in gray shows the average; B: The Matts grade significantly improved from 3.4 ± 0.5 
to 2.2 ± 0.8 (mean ± SD; t-test, P = 0.02) after the initiation of Qing Dai treatment. The line plotted in gray shows the average.
BA
Figure 2  Endoscopic finding before and after treatment. A: Before the initiation of Qing Dai, endoscopic examination showed severe ulcers and erosions in the 
rectum; B: After 3 mo of Qing Dai treatment, the mucosal damage completely disappeared. 
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tory effects by suppressing interferon-α, interleukin-6[13], 
and nuclear factor κB (NF-κB) production[14]. Xilei-san 
was also reported to decrease the expression of  toll-like 
receptor 4, NF-κB, and tumor necrosis factor-α in mice 
with oxazolone-induced colitis[15]. Interestingly, cytapher-
esis, which has been used in patients with active UC as a 
highly effective therapeutic, possesses a similar mecha-
nism of  action by decreasing reactive oxygen-producing 
neutrophils and interleukin-6 secretion[16]. In the present 
investigation, although we observed a strong hydroxyl 
radical scavenging effect in Qing Dai, further studies are 
warranted to fully understand the mechanisms of  action 
in UC patients.
This study has several limitations. First, this was not 
a double-blind placebo-controlled trial. Second, basic 
experiments using animal models were not conducted. In 
light of  these limitations, we are planning an in vivo study 
and a prospective multicenter double-blind placebo-
controlled trial to investigate the effects of  Qing Dai in 
patients with inflammatory bowel disease.
In conclusion, this investigation showed that oral 
Qing Dai is associated with significant clinical and en-
doscopic improvement of  UC in patients who maintain 
active disease despite receiving conventional medications. 
The hydroxyl radical scavenging effect appears to be one 
mode of  action of  Qing Dai. Our results suggest that 
Qing Dai may represent a clinically relevant intervention 
for patients with inflammatory bowel disease. Additional 
controlled trials using larger cohorts of  patients should 
be conducted to verify the findings of  this investigation.
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